Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss outcomes, according to a study presented at ...

Research from ENDO 2025 reveals that GLP-1 anti-obesity medications not only aid in weight loss but also improve testosterone ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...